Delivery Order SPE2DB22D3501-SPE2DB25FXA27
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,138.54 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vehicle running through December 2026 that provides comprehensive pharmaceutical and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 45 MG tablets (28-count unit dose packaging) on August 8, 2025, with an ultimate completion date of August 11, 2025. This competitively awarded, firm fixed-price delivery order has a ceiling value of $11,665.94 and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,383.94 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with a completion deadline of August 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed price pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $33,525.88 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-count units) valued at $7,265.22 under a firm fixed-price contract type. The award was made on July 23, 2025, with an ultimate completion date of July 24, 2025, and represents a non-competitive, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $39,491.47 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation. The pharmaceutical product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a $18,669.96 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $42,368.91 to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a $28,416.82 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 15, 2025, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award carries no set-aside designation, reflecting the company's proven capability to...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for RINVOQ ER 15 MG tablets (UU 30s) with a ceiling value of $14,051.64. This firm fixed-price delivery order, which represents no set-aside designation, is part of AmerisourceBergen's broader indefinite delivery contract (IDC) with DLA Troop Support Medical valued at $999.99 billion through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXA27Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $14,202.34 to AmerisourceBergen Drug Corp for RINVOQ ER 45 mg tablets (28-count units) on August 25, 2025, with an ultimate completion date of August 26, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is a child contract under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026 that enables the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide. RINVOQ ER (upadacitinib) is a Janus kinase (JAK) inhibitor used in the treatment of rheumatoid arthritis and other inflammatory conditions, reflecting the Defense Health Agency's medical supply requirements for active-duty personnel, veterans, and military beneficiaries. AmerisourceBergen's extensive portfolio of federal pharmaceutical contracts demonstrates its critical role in the DLA Medical Supply Chain, with the company consistently delivering competitively awarded orders across multiple therapeutic domains. The DLA Troop Support is advancing its Pharmaceutical Prime Vendor Global Program Generation V strategy, which contemplates multiple regional awards to support comprehensive global military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $14.2k | 8/25/25 |